Syneron Announces New Ground Breaking evolastin(TM) Procedure

One treatment procedure primed to propel facial aesthetic procedures forward with unique results and significant science.

Irvine, California—February 2, 2012-Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the global leader in medical aesthetic products and technology, announces the launch of evolastin(TM) – the industry’s first energy-based dermalremodeling procedure that delivers controlled radio frequency energy directly to the deepdermis to stimulate the skin’s natural production of collagen, elastin and hyaluronic acidin a single treatment.

A recent randomized and blinded clinical study published by leading dermatologists inthe journal Archives of Dermatology proved the unique and dramatic impact of evolastinfor patients seeking an alternative to address the loss of tautness and suppleness mostcommon with age. “It is unprecedented to be able to achieve results as effective andconsistent with a single energy-based procedure,” comments Macrene Alexiades-Armenakas, M.D., Ph.D, F.A.A.D, board-certified dermatologist in New York City, Assistant Clinical Professor at Yale University School of Medicine and lead investigatorof evolastin. “In a one-hundred patient multi-center study conducted using this procedure, we’ve seen continual textual, tone or elasticity in addition to volumetric improvements for up to eighteen months post procedure and patient satisfaction has been remarkably high and equally consistent.”

Unlike traditional energy-based procedures that aim to reach the dermis through thesurface, evolastin positions the entire energy directly at the base of the dermis usinginsulated microneedles that create a unique wound healing response. “evolastin is amajor step forward in the field of facial aesthetics,” says Amy Taub, M.D., board certified dermatologist at Advanced Dermatology in Lincolnshire, Illinois and Assistant Clinical Professor at Northwestern University. “This procedure gives patients of all skintypes results unlike any other energy-based procedure on the market – it addresses volume and lifts while improving skin quality and elasticity.”

evolastin(TM) is generally performed under local anesthetic in about an hour, allowing patients to drive home safely post-treatment and return to normal activities within 24 hours. Downtime is minimal with only minor redness, swelling or bruising for a few days.

“evolastin(TM) represents our commitment to scientific research and technological development,” said Louis P. Scafuri, Chief Executive Officer of Syneron Medical. “Theunique results of evolastin coupled with strong clinical evidence provides a uniqueminimally invasive solution for our customers, a revolutionary alternative for their patients and yet another exciting advancement in our field.”

For more information about evolastin or to locate a physician in your area, visit www.evolastin.com.

About Syneron Medical Ltd.

Syneron Medical Ltd. – a company devoted to real technology, real science and realresults – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation ofthe skin’s appearance through the treatment of superficial benign vascular and pigmentedlesions, and the treatment of acne, leg veins and cellulite. The Company sells its productsunder two distinct brands, Syneron and Candela. The Company’s aspiration andcommitment to innovation expands Syneron’s offering beyond medical device into thelargest in-demand applications in beauty – skin lightening. Founded in 2000, thecorporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are notstatements of historical fact (including statements containing “believes,” “anticipates,” “plans,” “expects,” “may,” “will,” “would,” “intends,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materiallyfrom those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that themerger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.’s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.’s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The any future dispositions or strategic transactions that may be undertaken. These forward looking statements should not be relied upon as representing Syneron Medical Ltd.’s views as of any date after the date of this document.

Contacts:
Syneron – Public Relations
pr@syneron.com

KELZ PR – 646-450-5359
Melissa Kelz – Melissakelz@kelzpr.com
Patty Mathews – Pattymathews@kelzpr.com

Asaf Alperovitz
Chief Financial Officer
+ 972 73 244 2283

Source:  http://www.easyir.com/easyir/prssrel.do?easyirid=256C4E86057F2703&version=live&prid=847526